中國(guó)藥科大學(xué)藥學(xué)院研究生導(dǎo)師介紹：劉李

• 2025考研復(fù)試標(biāo)準(zhǔn)班
• 26考研全科上岸規(guī)劃營(yíng)「擇校▪規(guī)劃▪備考」
• 中國(guó)藥科大學(xué)2026考研專業(yè)課復(fù)習(xí)資料「真題▪筆記▪講義▪題庫(kù)」

劉李，男，中共黨員，博士，副教授，博士研究生導(dǎo)師，現(xiàn)任中國(guó)藥科大學(xué)藥學(xué)院藥代研究中心教師。

1、學(xué)習(xí)、工作經(jīng)歷

1999.9~2003.6中國(guó)藥科大學(xué)藥學(xué)專業(yè)（本科）
2004.9~2007.6中國(guó)藥科大學(xué)藥理學(xué)專業(yè)（碩士，導(dǎo)師：劉曉東教授）
2007.9~2010.6中國(guó)藥科大學(xué)藥劑學(xué)專業(yè)（博士，導(dǎo)師：劉曉東教授）
2010.7~2012.4中國(guó)藥科大學(xué)講師
2012.5~2013.5中國(guó)藥科大學(xué)副教授
2013.6~至今中國(guó)藥科大學(xué)副教授、碩士研究生導(dǎo)師

2015.6~至今中國(guó)藥科大學(xué)副教授、博士研究生導(dǎo)師

2、科研與教學(xué)

主要研究方向?yàn)樗幬锎�謝動(dòng)力學(xué)。科研上主持2011年國(guó)家自然科學(xué)基金青年項(xiàng)目1項(xiàng)（基于胰高血糖素樣肽-1釋放調(diào)控詮釋人參二醇型皂苷抗糖尿病作用及其機(jī)制，81102503）、2014年國(guó)家自然科學(xué)基金面上項(xiàng)目1項(xiàng)（基于CYP3A等CYP450酶活性誘導(dǎo)詮釋阿托伐他汀等他汀類藥物誘發(fā)新生糖尿病和加重糖尿病癥狀的作用及機(jī)制，81473273）、2015年和2014年中國(guó)藥科大學(xué)中央高校研究項(xiàng)目各1項(xiàng)；參與1項(xiàng)國(guó)家自然科學(xué)基金（81373482）和3項(xiàng)科技部“重大新藥創(chuàng)制”（2011ZX09102-009、2011ZX091022-022、2009ZX09501-003）的研究；主持創(chuàng)新藥物的臨床前藥代動(dòng)力學(xué)研究共5項(xiàng)；協(xié)助指導(dǎo)已畢業(yè)博士研究生8人、碩士生15人，獨(dú)立指導(dǎo)碩士研究生4人、本科實(shí)習(xí)生16人。

教學(xué)上主講本科生《藥物代謝動(dòng)力學(xué)》和《臨床藥物代謝動(dòng)力學(xué)》課程，擔(dān)任藥理學(xué)、藥代動(dòng)力學(xué)、臨床藥代動(dòng)力學(xué)實(shí)驗(yàn)授課。指導(dǎo)的本科論文一篇獲2013年校級(jí)本科優(yōu)秀畢業(yè)論文，一篇獲2011年江蘇省普通高校本�？苾�(yōu)秀畢業(yè)設(shè)計(jì)論文優(yōu)秀指導(dǎo)教師三等獎(jiǎng)（排名2）。主持2014年“中國(guó)藥科大學(xué)實(shí)驗(yàn)教學(xué)改革研究重點(diǎn)課題”1項(xiàng)，主持“中國(guó)藥科大學(xué)教學(xué)改革研究一般課題”2項(xiàng)。指導(dǎo)2014年度“國(guó)家級(jí)大學(xué)生創(chuàng)新創(chuàng)業(yè)訓(xùn)練計(jì)劃項(xiàng)目”和2013年度“江蘇省大學(xué)生創(chuàng)新創(chuàng)業(yè)訓(xùn)練計(jì)劃項(xiàng)目”各1項(xiàng)。

3、近年來(lái)發(fā)表有代表性學(xué)術(shù)論文(*通訊作者)

1. Liu C, Hu M, Guo H, Zhang M, Zhang J, Li F, Zhong Z, Chen Y, Li Y, Xu P, Li J, Liu L*, Liu X*. Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats Following Oral Administration. Drug Metab Dispos. 2015; doi:10.1124/dmd.115.064881

2. Li F, Xu D, Shu N, Zhong Z, Zhang M, Liu C, Ling Z, Liu L*, Liu X*. Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution. Xenobiotica. 2015; 45(9): 794-802.

3. Jiang S, Zhao W, Chen Y, Zhong Z, Zhang M, Li F, Xu P, Zhao K, Li Y, Liu L*, Liu X*. Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in rats. Drug Metab Pharmacokinet.  2015; 30(3): 240-6.

4. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015; 54(2):179-93.

5. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014; 5: 273.

6. Zhang J, Zhang M, Sun B, Li Y, Xu P, Liu C, Liu L*, Liu X*. Hyperammonemia enhances the function and expression of P-glycoprotein and Mrp2 at the blood-brain barrier through NF-κB. J Neurochem. 2014 Dec; 131(6):791-802.

7. Xu D, Li F, Zhang M, Zhang J, Liu C, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, Liu L*, Liu XD*. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2014; 35(9): 1215-25.

8. Liu C, Hu MY, Zhang M, Li F, Li J, Zhang J, Li Y, Guo HF, Xu P, Liu L*, Liu XD*. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism. 2014; 63(10): 1342-51.

9. Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L*, Liu XD*. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin. 2014; 35(6): 792-805.

10. Li J, Wang X, Liu H, Guo H, Zhang M, Mei D, Liu C, He L, Liu L*, Liu X*. Impaired hepatic and intestinal ATP-binding cassette transporter G5/8 was associated with high exposure of β-sitosterol and the potential risks to blood-brain barrier integrity in diabetic rats. J Pharm Pharmacol. 2014; 66(3):428-36.

11. Hu N, Hu MY, Duan R, Liu C, Guo HF, Zhang M, Yu YL, Wang XT, Liu L*, Liu XD*. The increased levels of fatty acids contributed to induction of hepatic CYP3A4 activityinduced by diabetes. An in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 2014; 124(4): 433-44.

12. Jia LL, Zhong ZY, Li F, Ling ZL, Chen Y, Zhao WM, Li Y, Jiang SW, Xu P, Yang Y, Hu MY, Liu L*, Liu XD*. The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic Acid in rats. J Pharmacol Sci. 2014; 124(4): 468-79.

13. Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L*, Liu X*. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci. 2013; 102(8): 2819-36.

14. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, Jin S, Wang XT, Liu L*, Liu XD*. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol. 2013; 217(2):185-96.

15. Yu Y, Wang X, Liu C, Yao D, Hu M, Li J, Hu N, Liu L*, Liu X*. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013; 266(3): 375-84.

16. Liu H, Liu L [Co-first author], Li J, Mei D, Duan R, Hu N, Guo H, Zhong Z, Liu X. Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Bcrp Activities and Expressions to Increased Exposure of Oral Glibenclamide in Streptozotocin-induced Diabetic Rats. Drug Metab Dispos. 2012; 40(6): 1104-12.

17. Duan R, Hu N, Liu HY, Li J, Guo HF, Liu C, Liu L*, Liu XD*. Biphasic regulation of P-glycoprotein function and expression by NO donors in Caco-2 cells. Acta Pharmacol Sin. 2012 Jun;33(6):767-74.

18. Yao D*, Liu L*, Jin S, Li J, Liu XD. Overexpression of multidrug resistance-associated protein 2 in the brain of pentylenetetrazole-kindled rats. Neuroscience. 2012; 227: 283-92.

19. Liu L, Yu YL, Liu C, Wang XT, Liu XD, Xie L. Insulin deficiency induces abnormal increase in intestinal disaccharidase activities and expression under diabetic states, evidences from in vivo and in vitro study. Biochem Pharmacol. 2011; 82(12): 1963-70. [IF: 4.576]

20. Liu L, Pan X, Liu HY, Liu XD, Yang HW, Xie L, Cheng JL, Fan HW, Xiao DW. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin. 2011; 32(10): 1285-93.

21. Liu L, Ju HL, Zhang J, Liang Y, Liu XD, Xie L, Wang GJ. Development and validation of an LC-MS/MS method for determination of vorinostat in beagle dog plasma and its application to a pharmacokinetic study. Asian J Pharmacodyn Pharmacokinet. 2010; 10(3): 209-219.

22. Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD, Xie L, Wang GJ.  Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(4): 371-81.

23. Liu L, Deng YX, Liang Y, Pang XY, Liu XD, Liu YW, Yang JS, Xie L, Wang GJ. Increased oral AUC of baicalin in streptozotocin-induced diabetic rats due to the increased activity of intestinal β-glucuronidase. Planta Med. 2010; 76(1): 70-5.

4、聯(lián)系方式

(1)電話：025-83271006

(2)手機(jī)：13914732571

(3)E-mail：liulee@yeah.net